Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer

Prostate

Volumn 69, Issue 4, 2009, Pages 346-351

  Yasuda, Kenji ^a   Nagakawa, Osamu ^b   Akashi, Takuya ^a   Fujiuchi, Yasuyoshi ^a   Koizumi, Keiichi ^a   Komiya, Akira ^a   Saiki, Ikuo ^a   Fuse, Hideki ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Mihama Hospital   (Japan)

Author keywords

AHGF; Prostate cancer; THGF

Indexed keywords

SCATTER FACTOR; TUMOR MARKER; LEUKOCYTE ELASTASE INHIBITOR; SPINT1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN BLOOD LEVEL; TUMOR DIFFERENTIATION; ADENOCARCINOMA; BLOOD; DISEASE COURSE; MIDDLE AGED; PROSTATE DISEASE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; HEPATOCYTE GROWTH FACTOR; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC DISEASES; PROSTATIC NEOPLASMS; PROTEINASE INHIBITORY PROTEINS, SECRETORY; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 59849099060     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20890     Document Type: Article

References (29)

1. Sakata H, Takayama H, Sharp R, Rubin JS, Merlino G, LaRochelle WJ. Hepatocyte growth factor/scatter factor overexpression induces growth, abnormal development, and tumor formation in transgenic mouse livers. Cell Growth Differ 1996;7:1513-1523.
2. Tajima H, Matsumoto K, Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 1992;202:423-431.
3. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, Gaudino G, Tamagnone L, Coffer A, Comoglio PM. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-641.
4. Miyazawa K, Shimomura T, Kitamura A, Kondo J, Morimoto Y, Kitamura N. Molecular cloning and sequence analysis of the cDNA for a human seine protease responsible for activation of hepatocyte growth factor. Structural similarity of the protease precursor to blood coagulation factor XII. J Biol Chem 1993;268:10024-10028.
5. Miyazawa K, Shimomura T, Kitamura N. Activation of hepatocyte growth factor in the injured tissues is mediated by hepatocyte growth factor activator. J Biol Chem 1996;271:3615-3618.
6. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000;275:36720-36725.
7. Shimomura T, Denda K, Kitamura A, Kawaguchi T, Kito M, Kondo J, Kagaya S, Qin L, Takata H, Miyazawa K, Kitamura N. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:6370-6376.
8. Kawaguchi T, Qin L, Shimomura T, Kondo K, Matsumoto K, Denda K, Kitamura N. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor. J Biol Chem 1997;272:27558-27564.
9. Oberst M, Anders J, Xie B, Singh B, Ossandon M, Johnson M, Dickson RB, Lin CY. Matriptase and HAI-1 are expressed by normal and malignant epithelial cells in vitro and in vivo. Am J Pathol 2001;158:1301-1311
10. Parr C, Watkins G, Mansel RE, Jiang WG. The hepatocyte growth factor regulatory factors in human breast cancer. Clin Cancer Res 2004;10:202-211.
11. Nagakawa O, Yamagishi T, Fujiuchi Y, Junicho A, Nagaike K, Fuse H. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer. Eur Urol 2005;48:686-690.
12. Nagakawa O, Yamagishi T, Akashi T, Nagaike K, Fuse H. Serum hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2) in prostate cancer. Prostate 2006;66:447-452.
13. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-396.
14. Kurimoto S, Moriyama N, Horie S, Sakai M, Kameyama S, Akimoto Y, Hirano H, Kawabe K. Co-expression of hepatocyte growth factor and its receptor in human prostate cancer. Histochem J 1998;30:27-32.
15. Nishimura K, Kitamura M, Takada S, Nonomura N, Tsujimura A, Matsumiya K, Miki T, Matsumoto K, Okuyama A. Regulation of invasive potential of human prostate cancer cell lines by hepatocyte growth factor. Int J Urol 1998;5:276-281.
16. Nagakawa O, Murakami K, Yamaura T, Fujiuchi Y, Murata J, Fuse H, Saiki I. Expression of membrane-type 1 matrix metal-loproteinase (MT1-MMP) on prostate cancer cell lines. Cancer Lett 2000;155:173-179.
17. Fujiuchi Y, Nagakawa O, Murakami K, Fuse H, Saiki I. Effect of hepatocyte growth factor on invasion of prostate cancer cells. Oncol Rep 2003;10:1001-1006.
18. Naughton M, Picus J, Zhu X, Catalona WJ, Vollmer RT, Humphrey PA. Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. J Urol 2001;165:1325-1328.
19. Zhu X, Humphrey PA, Overexpression and, regulation of expression of scatter factor/hepatocyte growth factor in prostatic carcinoma. Urology 2000;56:1071-1074.
20. Humphrey PA, Halabi S, Picus J, Sanford B, VogelzangNJ, Small EJ, Kantoff PW. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone-refractory prostate cancer: Results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer 2006;4:269-274.
21. Naldini L, Tamagnone L, Vigna E, Sachs M, Hartmann G, Birchmeier W, Daikuhara Y, Tsubouchi H, Blasi F, Comoglio PM. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 1992;11:4825-4833.
22. Kataoka H, Miyata S, Uchinokura S, Itoh H. Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor. Cancer Metastasis Rev 2003;22:223-236.
23. Shimomura T, Kondo J, Ochiai M, Naka D, Miyazawa K, Morimoto Y, Kitamura N. Activation of the zymogen of hepatocyte growth factor activator by thrombin. J Biol Chem 1993;268:22927-22932.
24. Yamauchi M, Kataoka H, Itoh H, Seguchi T, Hasui Y, Osada Y. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma. J Urol 2004;171:890-896.
25. Kataoka H, Hamasuna R, Itoh H, Kitamura N, Koono M. Activation of hepatocyte growth factor/scatter factor in color-ectal carcinoma. Cancer Res 2000;60:6148-6159.
26. Nagata K, Hirono S, Ido A, Kataoka H, Moriuchi A, Shimomura T, Hori T, Hayashi K, Koono M, Kitamura N, Tsubouchi H. Expression of hepatocyte growth factor activator and hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma. Biochem Biophys Res Commun 2001;289:205-211.
27. Kataoka H, Shimomura T, Kawaguchi T, Hamasuna R, Itoh H, Kitamura N, Miyazawa K, Koono M. Hepatocyte growth factor activator inhibitor type 1 is a specific cell surface binding protein of hepatocyte growth factor activator (HGFA) and regulates HGFA activity in the pericellular microenvironment. J Biol Chem 2000;275:40453-40462.
28. Denda K, Shimomura T, Kawaguchi T, Miyazawa K, Kitamura N. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1. J Biol Chem 2002;277:14053 -14059.
29. Knudsen BS, Lucas JM, Fazli L, Hawley S, Falcon S, Coleman IM, Martin DB, Xu C, True LD, Gleave ME, Nelson PS, Ayala GE. Regulation of hepatocyte activator inhibitor-1 expression by androgen and oncogenic transformation in the prostate. Am J Pathol 2005;167:255-266.